Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

25.85 -0.95 (-3.54%)
Delayed Quote Updated: 11:52 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nurix Therapeutics, Inc. - Common stock

News headline image
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Nurix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
From Nurix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
From Nurix Therapeutics, Inc.
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
Nurix Therapeutics Inc. (NASDAQ: NRIX) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors
From Toll Brothers, Inc.
Via GlobeNewswire
News headline image
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.